Use of taxanes in the treatment of patients with breast cancer has increased dramatically over the past 8 years.
Partridge
A
A
Winer
E
E
D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000523:psychology; D000077143:Docetaxel; D004363:Drug Utilization; D005260:Female; D006801:Humans; D008495:Medical Oncology / Q000379:methods / Q000706:statistics & numerical data; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D018579:Patient Selection; D011788:Quality of Life; D016019:Survival Analysis; D043823:Taxoids; D016896:Treatment Outcome
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel